MarginsXMarginsX
Home › Markets › Health Care › BHVN

Biohaven Ltd. Common Shares (BHVN)

BHVN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$13.80
-0.14% on the day
Market cap
$2.1B
Mid cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerBHVN on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2022
SEC CIK0001935979
SEC industry codePharmaceutical Preparations
Incorporated inVirgin Islands, British

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
2.4 months
$95.8M cash at September 30, 2026
Share count, 1 year
+42.7%
2025-11-06 to 2026-10-26 · +88.3% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
$30.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Going Concern In accordance with Accounting Standards Codification ( ASC ) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued."
10-Q 2026-10-29
Cash and burn$95.8M cash; operating cash flow -$118.1M a quarter.Report 2026-09-30
Shares outstanding151,058,781 (2026-10-26); 105,855,155 a year earlier; 80,233,656 three years earlier.Cover page 2026-10-26
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-05-04
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Stamford, Connecticut, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $30.6M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$129.3M-$106.9M$95.8MNo debt tagsNeeds four quarters10-Q 2026-10-29
Q2 2026
2026-06-30
Not filed-$137.3M-$85.1M$238.0MNo debt tagsNeeds four quarters10-Q 2026-08-10
Q1 2026
2026-03-31
Not filed-$130.5M-$149.9M$273.1MNo debt tagsNeeds four quarters10-Q 2026-05-04
Q4 2025
2025-12-31
Not filed-$145.6M-$130.7M$230.0MNo debt tagsNeeds four quarters10-K 2026-03-02
Q3 2025
2025-09-30
Not filed-$173.4M-$145.7M$184.8MNo debt tagsNeeds four quarters10-Q 2026-10-29
Q2 2025
2025-06-30
Not filed-$198.1M-$167.9M$165.8MNo debt tagsNeeds four quarters10-Q 2026-08-10
Q1 2025
2025-03-31
Not filed-$221.7M-$165.1M$98.4MNo debt tagsNeeds four quarters10-Q 2026-05-04
Q4 2024
2024-12-31
Not filed-$186.8M-$170.7M$99.1MNo debt tagsNeeds four quarters10-K 2026-03-02

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-04
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-03-13

Source: SEC EDGAR submissions feed, 284 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.6%
1 month+21.0%
3 months-6.9%
Year to date+22.4%
1 year+71.0%
From 52-week high-18.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
IMNMImmunome Inc.$17.61-6.18%$2.1B
AUPHAurinia Pharmaceuticals Inc$15.48-1.59%$2.1B
PVLAPalvella Therapeutics Inc.$144.60-5.17%$2.1B
SDGRSchrodinger Inc.$27.36-7.35%$2.1B
SEPNSepterna Inc.$41.67-2.18%$2.0B
TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$46.56-1.15%$2.0B
VERAVera Therapeutics Inc.$26.97-4.02%$1.9B
HRMYHarmony Biosciences Holdings Inc.$32.96-2.37%$1.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier